POLICY NAME	Cablivi (caplacizumab)	POLICY #	3186P
-------------	------------------------	----------	-------

Criteria

Coverage Criteria for Thrombocytopenic Purpura (TTP)		
	Diagnosis of acquired thrombocytopenic purpura (TTP)	
	Cablivi will be used in combination with plasma exchange therapy and immunosuppressants • Therapy is limited to 30 days after discontinuation of plasma exchange	
	Age 18 years or older	
	Prescribed by or in consultation with a hematologist	
	First dose given by healthcare provider as IV injection	